Evidence map›Paper›PMID 35173396›Full record

ArticleJournal of current glaucoma practice

Jessica Sze Chia Ng, Yi Xin Tan, Nor Amalina Ahmad Alwi, Kar Ming Yee, Ahmad Hazri Abdul Rashid, Ka-Liong Tan, Chuei Wuei Leong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica Sze Chia NgFormulation R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.
Yi Xin TanFormulation R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.
Nor Amalina Ahmad AlwiFormulation R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.
Kar Ming YeeFormulation R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.
Ahmad Hazri Abdul RashidIndustrial Biotechnology Research Centre, SIRIM Berhad, Shah Alam, Selangor, Malaysia.
Ka-Liong TanFaculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia (USIM), Persiaran Ilmu, Putra Nilai, Nilai, Negeri Sembilan, Malaysia.
Chuei Wuei LeongFormulation R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Selangor, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIM AND

objectiveTo evaluate the safety of two new generic ophthalmic formulations, Latanost MATERIALS AND

methods

resultsThe mean cell viability percentage of LTN and XLT was 70.5 and 75.7%, respectively, whereas, for LTC and XLC, the percentage viability was 95.3 and 85.7%, respectively. The two new generic formulations (LTN and LTC) did not reduce the cell viability of the RhCE tissue to ≤60%. Thus, both can be considered as nonirritant.

conclusionBoth newly developed generics are nonocular irritants. CLINICAL SIGNIFICANCE: This study informs the safety assessment of new generic antiglaucoma ophthalmic solutions applicable for long-term glaucoma treatment. The formulations aim to keep eye irritation to a minimum level. HOW TO CITE THIS ARTICLE: Ng JSC, Tan YX, Alwi NAA,

Indexed as

Eye irritationGenericGlaucomaLatanoprostTimolol

Identifiers

PMID35173396
PMCPMC8807938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.